GTHP · XBRL financial data

Guided Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GTHP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0	32*	6	0	0	1*	0	117	60	year only	0	0
Cost of goods and services sold	4	16*	2	0	0	3*	0	38	25	year only	0	0
Gross profit	(4)	16*	4	0	0	(2)*	0	79	35	—	0	0
Research and development	69	86*	54	222	111	140*	74	133	136	127*	45	34
General and administrative	481	350*	236	364	374	323*	267	658	362	1,018*	451	423
Total operating expenses	619	501*	363	655	561	532*	414	842	520	1,168*	302	478
Operating income (loss)	(623)	(485)*	(359)	(655)	(561)	(534)*	(414)	(763)	(485)	(710)*	(302)	(478)
Interest expense	71	72*	64	75	108	134*	147	157	129	184*	151	136
Other income (expense)	0	38*	1	12	(93)	209*	98	64	(257)	(508)*	(198)	(127)
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(677)	(386)*	(402)	(709)	(654)	(652)*	(0)	(811)	(742)	(1,218)*	(500)	(605)
Earnings per share, basic USD per share	(0.01)	—	(0.01)	(0.01)	(0.01)	—	(0.01)	(0.01)	(0.01)	(0.01)*	(0.01)	(0.01)
Earnings per share, diluted USD per share	(0.01)	(0.01)*	(0.01)	(0.01)	(0.01)	—	(0.01)	(0.01)	(0.01)	(0.01)*	(0.01)	(0.01)
Weighted average shares, basic thousands of shares	51,473	—	—	—	57,039	—	68,291	78,838	81,689	84,623*	88,836	96,536
Weighted average shares, diluted thousands of shares	51,473	52,742*	55	55,986	57,039	—	68,291	78,838	81,689	84,623*	88,836	96,536

Fiscal quarters (GTHP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	731	591	445	275	194	388	115	185	87	63	369	12
Accounts receivable	7	7	7	2	2	3	2	8	6	4	4	4
Inventory	648	632	632	632	636	633	633	595	583	448	469	500
Total current assets	1,578	1,393	1,240	1,021	1,043	1,197	811	811	799	605	911	527
Property and equipment, net	35	32	30	28	25	23	21	18	18	16	13	11
Right-of-use asset	247	227	207	185	164	141	118	94	69	686	663	640
Total assets	1,877	1,669	1,494	1,251	1,249	1,378	967	940	903	1,324	1,604	1,195
Accounts payable	2,153	1,991	1,924	2,143	2,100	2,094	2,152	2,255	2,382	2,416	2,277	2,347
Accrued liabilities	807	970	780	840	923	1,011	1,062	1,117	952	1,718	1,129	1,242
Current portion of long-term debt	0	0	—	—	—	—	—	—	—	—	—	—
Total current liabilities	4,834	4,809	5,342	5,732	6,025	6,155	5,899	6,377	6,470	6,636	5,962	6,169
Lease liability, non-current	179	155	130	104	76	49	20	0	0	651	627	602
Total liabilities	5,527	5,475	5,506	5,918	6,167	6,267	5,995	6,412	6,549	7,330	6,780	6,958
Accumulated deficit	(150,649)	(151,118)	(151,559)	(152,317)	(153,009)	(153,709)	(154,172)	(155,028)	(155,813)	(157,055)	(158,068)	(158,672)
Total stockholders' equity	(3,650)	(3,806)	(4,012)	(4,667)	(4,918)	(4,889)	(5)	(5,472)	(5,646)	(6,006)	(5,176)	(5,763)
Total liabilities and equity	1,877	1,669	1,494	1,251	1,249	1,378	967	940	903	1,324	1,604	1,195
Common shares outstanding (cover page) thousands of shares	52,096	55,613	55,685	56,550	61,015	77,968	78,910	80,284	83,599	96,351	96,537	96,537

Fiscal quarters (GTHP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(677)	(386)*	(402)	(709)	(654)	(652)*	(0)	(811)	(742)	(1,218)*	(500)	(605)
Stock-based compensation	177*	(54)*	30	30*	73*	(13)*	0	330*	22*	25*	68	11*
Net cash from operating activities	(473)*	(336)*	(100)	(214)*	(473)*	(332)*	(331)	(169)*	(277)*	(291)*	(617)	(319)*
Purchases of property and equipment	0*	0*	—	—	—	0*	—	—	—	0*	—	—
Net cash from investing activities	—	—	—	—	—	0*	—	—	—	0*	—	—
Proceeds from issuing common stock	—	0*	—	—	—	535*	205	0*	—	year only	0	0*
Net cash from financing activities	(154)*	196*	(46)	44*	392*	526*	58	239*	181*	267*	923	(38)*
Net change in cash	—	year only	(146)	—	—	year only	(273)	—	—	—	—	—

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Mountain Crest Acquisition Corp. V	18	not reported	(79)*	2.9M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Co-Diagnostics	3,650	166	(7,153)*	6.3M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Lifeward	9,448	6,623	(6,005)*	2.8M	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Medinotec	2,584	3,201	108*	11.8M	—	Q2 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.